The addition of topotecan to carboplatin and paclitaxel as first-line therapy for advanced ovarian cancer; is it possible only with peripheral blood stem cell support?
about
SCOTROC 2B: feasibility of carboplatin followed by docetaxel or docetaxel-irinotecan as first-line therapy for ovarian cancer.Topoisomerase I (Top1): a major target of FL118 for its antitumor efficacy or mainly involved in its side effects of hematopoietic toxicity?Camptothecin (CPT) and its derivatives are known to target topoisomerase I (Top1) as their mechanism of action: did we miss something in CPT analogue molecular targets for treating human disease such as cancer?
P2860
The addition of topotecan to carboplatin and paclitaxel as first-line therapy for advanced ovarian cancer; is it possible only with peripheral blood stem cell support?
description
2000 nî lūn-bûn
@nan
2000 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
The addition of topotecan to c ...... heral blood stem cell support?
@ast
The addition of topotecan to c ...... heral blood stem cell support?
@en
The addition of topotecan to c ...... heral blood stem cell support?
@nl
type
label
The addition of topotecan to c ...... heral blood stem cell support?
@ast
The addition of topotecan to c ...... heral blood stem cell support?
@en
The addition of topotecan to c ...... heral blood stem cell support?
@nl
prefLabel
The addition of topotecan to c ...... heral blood stem cell support?
@ast
The addition of topotecan to c ...... heral blood stem cell support?
@en
The addition of topotecan to c ...... heral blood stem cell support?
@nl
P2093
P1476
The addition of topotecan to c ...... heral blood stem cell support?
@en
P2093
P577
2000-01-01T00:00:00Z